Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3340002

Cc1ccc(C(N)=O)cc1-c1ccc(OCCNC2CCC(C)(C)CC2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.42
MAPK14 Q16539 8/20 0.42
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MCHR1 Q99705 1/20 0.40
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HSPB1 P04792 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK11 Q15759 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
CHEK2 O96017 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12651502 0.95 MAPK14 (0.46) ABL1MAPK14RARBRARGALDH1A1
Trifluoroacetic Acid SCHEMBL3340017 0.85 OPRM1 (0.51) ABL1MAPK14HSPB1CYP2C9MAPK11
Trifluoroacetic Acid SCHEMBL1785741 0.84 SUCNR1 (0.42) RARBRARGALDH1A1KDM4ETDP1
Trifluoroacetic Acid SCHEMBL3341169 0.82 ALDH1A1 (0.42) RARBRARGALDH1A1MCHR1KDM4E
SCHEMBL1789424 0.80 ALDH1A1 (0.50) RARBRARGALDH1A1KDM4ETDP1
SCHEMBL15633601 0.79 ABL1 (0.42) ABL1MAPK14RARBRARGCHEK2
SCHEMBL12651066 0.78 OPRM1 (0.56) ABL1MAPK14HSPB1CYP2C9MAPK11
SCHEMBL12651253 0.78 SUCNR1 (0.43) RARBRARGALDH1A1KDM4ETDP1
Trifluoroacetic Acid SCHEMBL1790344 0.77 ALDH1A1 (0.47) RARBRARGALDH1A1MCHR1KDM4E
SCHEMBL12651059 0.76 ALDH1A1 (0.43) RARBRARGALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 ABL1 4109/4885MAPK14 4379/4885RARB 580/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 ABL1 4098/4885MAPK14 3307/4885RARB 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.